WA
NVO

Winfield Associates’s Novo Nordisk NVO Stock Holding History

Winfield Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,140
Closed -$31K – 468
2017
Q4 		$31K Hold
1,140
– – 0.02% 240
2017
Q3 		$27K Sell
1,140
-234
-17% -$5.29K 0.01% 251
2017
Q2 		$30K Buy
1,374
+672
+96% +$13.6K 0.02% 234
2017
Q1 		$12K Buy
702
+212
+43% +$3.69K 0.01% 366
2016
Q4 		$9K Sell
490
-420
-46% -$7.61K 0.01% 368
2016
Q3 		$19K Sell
910
-110
-11% -$2.73K 0.01% 260
2016
Q2 		$27K Buy
1,020
+20
+2% +$548 0.02% 226
2016
Q1 		$27K Buy
+1,000
New +$26.8K 0.02% 210

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Winfield Associates's NVO Position: Q1 2018 in Review

Winfield Associates sold out of Novo Nordisk (NVO) in Q1 2018, closing a stake of 1,140 shares — an estimated $31K sold.

Winfield Associates first reported a position in NVO in Q1 2016 and held it in 8 quarters. The position peaked at $31K in Q4 2017. 553 funds tracked by Wall St. Rank hold NVO as of Q1 2018.

  • Winfield Associates reported no remaining Novo Nordisk position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 1,140 Novo Nordisk shares in Q1 2018, an estimated $31K.
  • Winfield Associates first reported a position in Novo Nordisk in Q1 2016 and held it in 8 quarters.
  • Winfield Associates's Novo Nordisk position peaked at $31K in Q4 2017.
  • 553 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.